Aridis Pharmaceuticals, Inc. (ARDS) Touches $8.01 Low on Jun, 12; 3D Systems (DDD) Shorts Raised By 2.33%


3D Systems Corporation (NYSE:DDD) had an increase of 2.33% in short interest. DDD’s SI was 22.72M shares in June as released by FINRA. Its up 2.33% from 22.20 million shares previously. With 958,800 avg volume, 24 days are for 3D Systems Corporation (NYSE:DDD)’s short sellers to cover DDD’s short positions. The SI to 3D Systems Corporation’s float is 20.65%. The stock increased 1.53% or $0.12 during the last trading session, reaching $7.97. About 1.62M shares traded. 3D Systems Corporation (NYSE:DDD) has declined 28.72% since June 12, 2018 and is downtrending. It has underperformed by 33.15% the S&P500. Some Historical DDD News: 13/04/2018 – 3D SYSTEMS CORP – PREVAILED IN ACCOUNTING TRIAL FOR FORMER EMPLOYEE RON BARRANCO’S VIOLATION OF HIS NON-COMPETITION COVENANT; 22/04/2018 – DJ 3D Systems Corporation, Inst Holders, 1Q 2018 (DDD); 16/03/2018 – 3D SYSTEMS CORP DDD.N : DEUTSCHE BANK RAISES TARGET PRICE TO $13 FROM $9; 02/05/2018 – 3D SYSTEMS 1Q ADJ LOSS/SHR 3C, EST. EPS 1C; 14/03/2018 – 3D SYSTEMS 4Q REV. $177.3M, PRELIM. $176M-$178M; 18/04/2018 – Artec 3D Announces Integration of Handheld Scanners with 3D Systems’ Geomagic Freeform; 13/04/2018 – 3D Systems Prevails in Acctg Trial for Former Employee’s Violation of Non-Competition Covenant; Court Orders Disgorgement; 26/04/2018 – 3D Systems’ Figure 4™ 3D Printing Platform Selected for U.S. Air Force Research into Rapid Part Replacement; 10/05/2018 – 3D Systems and Huntington lngalls Industries Partner to Transform U.S. Navy Shipbuilding; 17/05/2018 – Yndetech Builds Fast-Growing Dental Implant Business in Italy with 3D Systems’ Direct Metal Printing

The stock of Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) reached all time low today, Jun, 12 and still has $7.45 target or 7.00% below today’s $8.01 share price. This indicates more downside for the $64.94M company. This technical setup was reported by Barchart.com. If the $7.45 PT is reached, the company will be worth $4.55 million less. The stock decreased 6.10% or $0.52 during the last trading session, reaching $8.01. About 2,374 shares traded. Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) has 0.00% since June 12, 2018 and is . It has underperformed by 4.43% the S&P500.

More notable recent Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) news were published by: Prnewswire.com which released: “Aridis Pharmaceuticals Appoints Dr. Susan Windham-Bannister to Board of Directors – PRNewswire” on June 10, 2019, also Nasdaq.com with their article: “Energy Sector Update for 06/07/2019: RDS-A,RDS-B,MGY,PBR,NBLX – Nasdaq” published on June 07, 2019, Nasdaq.com published: “Athersys Presents Data From Its Acute Respiratory Distress Syndrome Clinical Trial at American Thoracic Society International Conference – Nasdaq” on May 20, 2019. More interesting news about Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) were released by: Prnewswire.com and their article: “Aridis Pharmaceuticals Announces First Quarter 2019 Results – PRNewswire” published on May 14, 2019 as well as Globenewswire.com‘s news article titled: “Athersys Announces Fast Track Designation From FDA for MultiStem® Program for Acute Respiratory Distress Syndrome – GlobeNewswire” with publication date: May 14, 2019.

Aridis Pharmaceuticals Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies to treat life-threatening infections. The company has market cap of $64.94 million. The Company’s lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. It currently has negative earnings. The firm is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb that is in Phase IIa trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 to treat infections caused by A. baumannii; AR-201, an anti- respiratory syncytial virus F-protein mAb; and AR-501, an anti-infective therapy to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients.

Analysts await Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) to report earnings on August, 13. After $-0.99 actual EPS reported by Aridis Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 10.10% negative EPS growth.

More notable recent 3D Systems Corporation (NYSE:DDD) news were published by: Finance.Yahoo.com which released: “3D Systems vs. Stratasys: Which Had the Better Q1 Earnings Results? – Yahoo Finance” on May 22, 2019, also Finance.Yahoo.com with their article: “Is Nabors Industries Ltd. (NBR) A Good Stock To Buy ? – Yahoo Finance” published on June 10, 2019, Foxbusiness.com published: “Carbon IPO Watch: Is the 3D Printing Unicorn Preparing to Go Public? – Fox Business” on May 26, 2019. More interesting news about 3D Systems Corporation (NYSE:DDD) were released by: Finance.Yahoo.com and their article: “Did 3D Systems Corporation (NYSE:DDD) Insiders Sell Shares? – Yahoo Finance” published on May 08, 2019 as well as Finance.Yahoo.com‘s news article titled: “Is 3D Systems Corporation (DDD) A Good Stock To Buy? – Yahoo Finance” with publication date: May 02, 2019.

3D Systems Corporation, through its subsidiaries, provides 3D printing services and products worldwide. The company has market cap of $930.03 million. The companyÂ’s 3D printers transform data input generated by 3D design software, CAD software, or other 3D design tools into printed parts using a range of print materials, including plastic, nylon, metal, composite, elastomeric, wax, polymeric dental materials, and Class IV bio-compatible materials. It currently has negative earnings. It offers various 3D printing technologies, such as stereolithography, selective laser sintering, direct metal printing, multijet printing, and colorjet printing.

Investors sentiment increased to 1.43 in 2019 Q1. Its up 0.44, from 0.99 in 2018Q4. It improved, as 13 investors sold 3D Systems Corporation shares while 48 reduced holdings. 32 funds opened positions while 55 raised stakes. 80.47 million shares or 1.46% more from 79.31 million shares in 2018Q4 were reported. Brown Advisory holds 0% of its portfolio in 3D Systems Corporation (NYSE:DDD) for 104,568 shares. Hightower Advsrs Lc, Illinois-based fund reported 30,221 shares. Gamco Investors Inc Et Al has 0.01% invested in 3D Systems Corporation (NYSE:DDD). Proshare Advsr Limited Liability Corp reported 15,164 shares. Jane Street Gru Ltd reported 25,174 shares stake. Goldman Sachs Grp Inc has invested 0% of its portfolio in 3D Systems Corporation (NYSE:DDD). Clearbridge Invs Limited Liability Corp stated it has 0% of its portfolio in 3D Systems Corporation (NYSE:DDD). Captrust Fincl Advisors stated it has 0% in 3D Systems Corporation (NYSE:DDD). Metropolitan Life New York holds 0.02% in 3D Systems Corporation (NYSE:DDD) or 24,259 shares. Trustmark Commercial Bank Trust Department invested in 0% or 1,197 shares. Commonwealth Of Pennsylvania Pub School Empls Retrmt Systems invested in 39,243 shares or 0.01% of the stock. Commerzbank Aktiengesellschaft Fi has invested 0.09% in 3D Systems Corporation (NYSE:DDD). Svcs Automobile Association owns 17,506 shares or 0% of their US portfolio. North Star Invest Mgmt Corp holds 20 shares or 0% of its portfolio. Millennium Lc accumulated 112,461 shares.

3D Systems Corporation (NYSE:DDD) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.



Source link

Leave a Reply